Neimeth International Pharmaceuticals Plc Reports 9% Earnings Growth Amid Rising Costs
Neimeth International Pharmaceuticals Plc has seen a 9% year-on-year increase in profit after tax to N339.77 million for the nine months ending September 2025. The company's revenue surged by 62% to N5.01 billion, driven by increased product demand and better market penetration.
However, the company faced challenges such as a steep increase in financial costs, impacting its operating margin. Neimeth's gross profit also saw a significant increase to N2.49 billion.
Despite these challenges, the company's total assets grew by 11.3% to N13.35 billion. Neimeth continues to navigate Nigeria's challenging pharmaceutical environment amidst inflationary pressures and exchange rate volatility.
Plus234Feed summary based on reporting from Business Day. Read the original report below.
Read full article
Continue on Business Day
Get the week in one email
Top stories, NPFL results, the naira — every Friday morning. Free, one email a week.
Related Stories
NEM Insurance Reports Decline in Q1 Profit Despite Increased Premium Income
NEM Insurance Reports Strong Q2 2025 Revenue of N75.41 Billion, Exceeds Minimum Capital Requirements
Nigerian Health Stocks Surge on Investor Confidence in Pharma Growth
NAHCO Plc Reports 46% Profit Growth in Q3 2025
Nestlé Nigeria Reports N39.6bn Pre-Tax Profit in Q3 2025, Signals Strong Recovery
NAHCO Records 46% Profit Growth to N18 Billion in Q3 2025
Get Plus234Feed on messaging apps
Same headlines, delivered where you already scroll.
